Sildenafil plasma concentrations in two HIV patients with pulmonary hypertension treated with ritonavir-boosted protease inhibitors

Current HIV Research

Volumn 10, Issue 2, 2012, Pages 162-164

  Chinello, Pierangelo ^a   Cicalini, Stefania ^a   Pichini, Simona ^b   Pacifici, Roberta ^b   Tempestilli, Massimo ^a   Petrosillo, Nicola ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

HIV; Protease inhibitors; Pulmonary arterial hypertension; Sildenafil

Indexed keywords

ACENOCOUMAROL; AMPRENAVIR; CANRENONE; CLONAZEPAM; DIGOXIN; EMTRICITABINE; ENOXAPARIN; FOSAMPRENAVIR; FUROSEMIDE; LAMIVUDINE; LOPINAVIR; PHENOBARBITAL; RITONAVIR; SILDENAFIL; SPIRONOLACTONE; TENOFOVIR; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DEPRESSION; DRUG DEPENDENCE; DRUG MONITORING; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; LUNG ARTERY PRESSURE; MALE; MAXIMUM PLASMA CONCENTRATION; PULMONARY HYPERTENSION; TANDEM MASS SPECTROMETRY;

ADULT; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PIPERAZINES; PURINES; RITONAVIR; SULFONES; VASODILATOR AGENTS;

EID: 84860313369     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212799937263     Document Type: Article

References (15)

1. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-537.
2. Montani D, Chaumais MC, Savale L, et al. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009; 26: 813-25.
3. Gruenig E, Michelakis E, Vachiery JL, et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. J Clin Pharmacol 2009; 49: 1343-52.
4. Wilkins MR, Wharton J, Grimminger F, et al. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008; 32: 198-209.
5. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol 2000; 50: 99-107.
6. Pfizer labs. Revatio. Highlights of prescribing information. Center for Drug Evaluation and Research; available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021845 s007,022473s001lbl.pdf (last accessed September 13th, 2011).
7. Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 2005; 45: 987-1003.
8. Sekar V, Lefebvre E, De Marez T, et al. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects. Clin Drug Invest 2008; 28: 479-85.
9. Bratt G, Stahle L. Sildenafil does not alter nelfinavir pharmacokinetics. Ther Drug Monit 2003; 25: 240-2.
10. De Orsi D, Pellegrini M, Marchei E, et al. High performance liquid chromatography-diode array and electrospray-mass spectrometry analysis of vardenafil, sildenafil, tadalafil, testosterone and local anesthetics in cosmetic creams sold on theInternet web sites. J Pharm Biomed Anal 2009; 50: 362-9.
11. D'Avolio A, Baietto L, Siccardi M, et al. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new non nucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIVinfected patients. Ther Drug Monit 2008; 30: 662-9.
12. Van Heeswijk RPG, Veldkamp AI, Hoetelmans RMW, et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999; 13: F95-F9.
13. Jackson A, Hill A, Puls R, et al. Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers. J Antimicrob Chemother 2011; 66: 635-40.
14. Luber AD, Condoluci DV, Slowinski PD, et al. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. HIV medicine 2010; 11: 193-9.
15. Aschmann YZ, Kummer O, Linka A, et al. Pharmacokinetics and pharmacodynamics of sildenafil in a patient treated with human immunodeficiency virus protease inhibitors. Ther Drug Monit 2008; 30: 130-4.